ALK and non-small cell lung carcinoma: Their findings imply that this panel of three miRNAs has a lot of potential as an auxiliary diagnostic and that dynamic miRNAs biomarker monitoring may be beneficial for ALK-positive NSCLC patients treated using Crizotinib (Li et al. 2017).